APAC Autoimmune Disease Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.24 Billion |
| Market Size (2029) | USD 1.65 Billion |
| CAGR (2024 - 2029) | 5.96 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Autoimmune Disease Diagnostics Market Analysis
The Asia-Pacific Autoimmune Disease Diagnostics Market size is estimated at USD 1.24 billion in 2024, and is expected to reach USD 1.65 billion by 2029, growing at a CAGR of 5.96% during the forecast period (2024-2029).
The treatment of autoimmune diseases requires diagnosis of the disease at the onset of disease or later. This involves clinical laboratories checking for symptoms and providing the information to physician for better treatment of the disease. All the diagnostic laboratories do not have proper equipment for carrying out immunoassays. In that case, patient will face trouble in getting the tests done and then handing over the result to the physician. To overcome these problems, recently physicians and clinical laboratories started collaborating. Since, a physician knows where proper immunoassays and immunodiagnostics can be carried out, physician collaborates with that laboratory and suggests patient to get their tests done from there and the results will directly be sent to the physician. Furthermore, with increasing usage of Electronic Medical Records (EMR), labs have access to real-time test data and metrics extracted from the Laboratory Information System (LIS) and physicians too have access to these records, which increases efficiency in diagnosis, thus boosting autoimmune diagnostics market.
APAC Autoimmune Disease Diagnostics Market Trends
This section covers the major market trends shaping the APAC Autoimmune Disease Diagnostics Market according to our research experts:
Immunologic Assays Segment is Expected to Show Better Growth During the Forecast Years
Based on Diagnosis, the market is segmented into Regular Laboratory Tests, Inflammatory Markers, Immunologic Assays, Antibody Tests and Other Tests. The factors responsible for the growth of the market include cost-effectiveness, growth in the biotechnology and pharmaceutical sectors, and high sensitivity and specificity of immunoassays. When compared to conventional tests, immunologic assays have been proven to provide highly accurate results, even with very small samples.
Immunologic reactions are highly specific, as they can take place only in the presence of proper immunologic agents. This high specificity indicates high accuracy in results, enabling high sensitivity in the detection of diseases. It helps in easy detection and eliminates the need for secondary verification, which ultimately saves costs. Hence, owing to these factors, the segment is expected to show better growth in the forecast period.
APAC Autoimmune Disease Diagnostics Industry Overview
The market comprises of major market players, and these players are focusing on R&D activities and significant growth strategies. The major players into the Asia-Pacific autoimmune disease diagnostics market are Abbott Laboratories, BioMerieux, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens AG, Trinity Biotech and Thermo Fisher Scientific.
APAC Autoimmune Disease Diagnostics Market Leaders
-
Abbott Laboratories
-
BioMerieux
-
Bio-Rad Laboratories, Inc.
-
F. Hoffmann-La Roche Ltd
-
Thermo Fisher Scientific
*Disclaimer: Major Players sorted in no particular order
APAC Autoimmune Disease Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Public Awareness about Autoimmune Diseases
- 4.2.2 Partnerships with Physicians and Clinical Laboratories
- 4.2.3 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Disease Type
- 5.1.1 Systemic Autoimmune Disease
- 5.1.1.1 Rheumatoid Arthritis
- 5.1.1.2 Psoriasis
- 5.1.1.3 Systemic Lupus Erythematosus (SLE)
- 5.1.1.4 Multiple Sclerosis
- 5.1.1.5 Other Systemic Autoimmune Diseases
- 5.1.2 Localized Autoimmune Disease
- 5.1.2.1 Inflammatory Bowel Disease
- 5.1.2.2 Type 1 Diabetes
- 5.1.2.3 Thyroid
- 5.1.2.4 Other Localized Autoimmune Diseases
-
5.2 By Diagnosis
- 5.2.1 Regular Laboratory Tests
- 5.2.2 Inflammatory Markers
- 5.2.3 Immunologic Assays
- 5.2.4 Antibody Tests
- 5.2.5 Other Tests
-
5.3 Geography
- 5.3.1 Asia-Pacific
- 5.3.1.1 China
- 5.3.1.2 Japan
- 5.3.1.3 India
- 5.3.1.4 Australia
- 5.3.1.5 South Korea
- 5.3.1.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 BioMerieux
- 6.1.3 Bio-Rad Laboratories, Inc.
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 PerkinElmer, Inc.
- 6.1.6 Siemens AG
- 6.1.7 Trinity Biotech
- 6.1.8 Thermo Fisher Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAPAC Autoimmune Disease Diagnostics Industry Segmentation
Autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation.
| By Disease Type | Systemic Autoimmune Disease | Rheumatoid Arthritis |
| Psoriasis | ||
| Systemic Lupus Erythematosus (SLE) | ||
| Multiple Sclerosis | ||
| Other Systemic Autoimmune Diseases | ||
| By Disease Type | Localized Autoimmune Disease | Inflammatory Bowel Disease |
| Type 1 Diabetes | ||
| Thyroid | ||
| Other Localized Autoimmune Diseases | ||
| By Diagnosis | Regular Laboratory Tests | |
| Inflammatory Markers | ||
| Immunologic Assays | ||
| Antibody Tests | ||
| Other Tests | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific |
APAC Autoimmune Disease Diagnostics Market Research FAQs
How big is the Asia-Pacific Autoimmune Disease Diagnostics Market?
The Asia-Pacific Autoimmune Disease Diagnostics Market size is expected to reach USD 1.24 billion in 2024 and grow at a CAGR of 5.96% to reach USD 1.65 billion by 2029.
What is the current Asia-Pacific Autoimmune Disease Diagnostics Market size?
In 2024, the Asia-Pacific Autoimmune Disease Diagnostics Market size is expected to reach USD 1.24 billion.
Who are the key players in Asia-Pacific Autoimmune Disease Diagnostics Market?
Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd and Thermo Fisher Scientific are the major companies operating in the Asia-Pacific Autoimmune Disease Diagnostics Market.
What years does this Asia-Pacific Autoimmune Disease Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Asia-Pacific Autoimmune Disease Diagnostics Market size was estimated at USD 1.17 billion. The report covers the Asia-Pacific Autoimmune Disease Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Autoimmune Disease Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia-Pacific Autoimmune Disease Diagnostics Industry Report
Statistics for the 2024 Asia-Pacific Autoimmune Disease Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Autoimmune Disease Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
